Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuqing Lou

Showing results (101-110 of 115) with videos related to

Pageof 12
Sort By:
Ecotoxicology and Environmental Safety|July 18, 2021
Chemometric QSAR modeling of acute oral toxicity of Polycyclic Aromatic Hydrocarbons (PAHs) to rat using simple 2D descriptors and interspecies toxicity modeling with mouseGuohui Sun, Yifan Zhang, Luyu Pei, et al.
Translational Lung Cancer Research|July 17, 2025
Efficacy of immunotherapy in advanced <i>ALK</i>-rearranged non-small cell lung cancer patients with disease progression on ALK-TKIsDanni Wang, Yujing Li, Beibei Liu, et al.
Cell Death and Differentiation|April 4, 2026
RIPK3 sequentially recruits MLKL and RIPK1 to induce PANoptosis and chemokine productionYu Yang, Yue Wang, Yang Wang, et al.
Annals of Surgical Oncology|April 24, 2019
Adjuvant Chemotherapy Candidates in Stage I Lung Adenocarcinomas Following Complete LobectomyJie Qian, Jianlin Xu, Shuyuan Wang, et al.
NPJ Systems Biology and Applications|January 20, 2026
Machine learning prediction for AML based on 3D genome selected circRNAZhangli Yuan, Wenqian Yan, Ruoyao Wang, et al.
Biomarker Research|July 29, 2022
Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patientsJun Lu, Jun Wu, Yuqing Lou, et al.
International Journal of Cancer|October 5, 2019
Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studiesJie Qian, Wei Nie, Jun Lu, et al.
The European Respiratory Journal|December 23, 2018
Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapyJun Lu, Hua Zhong, Tianqing Chu, et al.
Cell Reports|March 29, 2026
Regulation of neuronal invasion of small cell lung cancer by STMN2/β-alanine-controlled metabolic reprogrammingYan Zhou, Runbo Zhong, Yanwei Zhang, et al.
The Oncologist|August 31, 2018
Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) <i>EGFR</i> Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II StudyLiwen Xiong, Rong Li, Jiayuan Sun, et al.
Pageof 12

Showing results (101-110 of 115) with videos related to

Sort By:
Pageof 12
Ecotoxicology and Environmental Safety|July 18, 2021
Chemometric QSAR modeling of acute oral toxicity of Polycyclic Aromatic Hydrocarbons (PAHs) to rat using simple 2D descriptors and interspecies toxicity modeling with mouseGuohui Sun, Yifan Zhang, Luyu Pei, et al.
Translational Lung Cancer Research|July 17, 2025
Efficacy of immunotherapy in advanced <i>ALK</i>-rearranged non-small cell lung cancer patients with disease progression on ALK-TKIsDanni Wang, Yujing Li, Beibei Liu, et al.
Cell Death and Differentiation|April 4, 2026
RIPK3 sequentially recruits MLKL and RIPK1 to induce PANoptosis and chemokine productionYu Yang, Yue Wang, Yang Wang, et al.
Annals of Surgical Oncology|April 24, 2019
Adjuvant Chemotherapy Candidates in Stage I Lung Adenocarcinomas Following Complete LobectomyJie Qian, Jianlin Xu, Shuyuan Wang, et al.
NPJ Systems Biology and Applications|January 20, 2026
Machine learning prediction for AML based on 3D genome selected circRNAZhangli Yuan, Wenqian Yan, Ruoyao Wang, et al.
Biomarker Research|July 29, 2022
Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patientsJun Lu, Jun Wu, Yuqing Lou, et al.
International Journal of Cancer|October 5, 2019
Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studiesJie Qian, Wei Nie, Jun Lu, et al.
The European Respiratory Journal|December 23, 2018
Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapyJun Lu, Hua Zhong, Tianqing Chu, et al.
Cell Reports|March 29, 2026
Regulation of neuronal invasion of small cell lung cancer by STMN2/β-alanine-controlled metabolic reprogrammingYan Zhou, Runbo Zhong, Yanwei Zhang, et al.
The Oncologist|August 31, 2018
Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) <i>EGFR</i> Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II StudyLiwen Xiong, Rong Li, Jiayuan Sun, et al.
Pageof 12